Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LXRX
DateTimeSourceHeadlineSymbolCompany
02/05/202421:05GlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202414:00GlobeNewswire Inc.Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202412:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
18/04/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host 2024 Investor DayNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/04/202413:00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
25/03/202413:20GlobeNewswire Inc.Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/03/202412:00GlobeNewswire Inc.New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202420:25Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202411:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202411:15GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202411:05GlobeNewswire Inc.Lexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202411:00GlobeNewswire Inc.Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDANASDAQ:LXRXLexicon Pharmaceuticals Inc
29/02/202421:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/02/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/01/202412:00GlobeNewswire Inc.Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202322:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202322:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202321:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
21/12/202321:15GlobeNewswire Inc.Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
30/11/202312:30GlobeNewswire Inc.Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)NASDAQ:LXRXLexicon Pharmaceuticals Inc
22/11/202312:30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX